MIAMI, FL / ACCESSWIRE / March 23, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. SXE, GALE, CPXX, and BLRX have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
Southcross Energy Partners, L.P. (NYSE: SXE)is a master limited partnership that provides natural gas gathering, processing, treating, compression and transportation services and NGL fractionation and transportation services. The stock has seen an increase in price and volume during the week of March 21st. Since Monday March 21st, the stock saw an opening price of $0.8199 and has climbed as high as $1.69 on Wednesday. This marks a move of more than 100% in 3 days.
Stay Informed and Up To Date On The Hottest Small Cap Nasdaq & OTC Plays. Get Them Here.
Galena Biopharma, Inc. (NASDAQ: GALE) last week reported a fourth quarter loss in its earning statement. The Portland, Oregon-based company said it had a loss of 12 cents per share. Losses, adjusted for one-time gains and costs, were 8 cents per share. For the year, the company reported that its loss widened to $63.9 million, or 41 cents per share. On Wednesday, however, the stock has continued to climb, following lows on Friday 3/18 of 0.82. As of Wednesday March 23, shares of GALE have moved up in price by as much as 51%.
Enjoy picks like this? Get These Alerts and More on top small cap Companies before They Rally, Text the phrase "StockAlerts" to 635-66
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX),announced today the pricing of an underwritten public offering of 4,000,000 shares of common stock. The shares of common stock are being offered at a price of $9.50 per share. Since last Monday, March 14 the stock has increased in price from $1.54 to highs on Wednesday 3/23 of $12.35, a difference of over 700%. The company is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer.
Stay Informed and Up To Date On The Hottest Small Cap Stocks; Free To Join Now
BioLineRx, Ltd. (NASDAQ: BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood circulation. The trial is designed to evaluate the ability of BL-8040, as a single agent, to promote stem cell mobilization for allogeneic transplantation. Since Monday March 21, shares of BLRX have increased in value from $1.05 to highs on Wednesday 3/23 of $1.26 and volume over the last 8 trading days has been trending above its 3 month average.
Small Cap Stock Alerts: Get Them straight to your Cell Phone. To Receive Our Winning Small Cap Stock Alerts For Free, text "StockAlerts" to 63566.
About TopNasdaqStocks.com
Looking for stock market and business news headlines? How about up to the minute information on mutual funds and ETFs? Don't forget about the top stock picks of 2016. TopNasdaqStocks.com has it all. Make sure to subscribe to our free newsletter and to receive free text message alerts on your phone, text "NASDAQ" to 77948.
Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor's or other person's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. Top Nasdaq Stocks has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding SXE, GALE, CPXX, or BLRX in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words "anticipate," "intend," "estimate," "believe," "expect," "plans," "should," "potential," "forecast," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company's actual results could differ materially from those described in any forward-looking statements contained herein. Top Nasdaq Stocks is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit http://topnasdaqstocks.com/index.php/disclaimer/ website for a more detailed discussion of risks and disclosures.
Contact:
Top Nasdaq Stocks
SOURCE: Top Nasdaq Stocks
